We are delighted that NRG Therapeutics has achieved a key milestone with the nomination of its first development candidate, NRG5051, and has secured a $5 million award from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). Domainex is proud to have supported this project by providing integrated lead optimization services including assay biology and medicinal and computational chemistry. During the period that Domainex worked on the programme, through careful design, we were able to make significant enhancements to the in vivo PK profiles of the lead series and ultimately identify NRG5051 as the development candidate.
- About
-
Services
-
Offerings
- Offerings
- ADME and Bioanalytical Sciences
- Analytical Chemistry
- Assay Development
- Biochemical Assays
- Biophysical Assays
- Cell Based Assays
- Computational Chemistry
- Fragment and Compound Screening
- Integrated Drug Discovery Services
- Medicinal Chemistry
- Project Management and Consultancy Services
- Protein Expression and Purification Services
- Structural Biology
- Synthetic Chemistry
- Virtual screening
-
Research Phases
- Research Phases
- Hit Identification
- Hit to Lead
- Lead Optimisation
- Therapeutic Areas
- Target Classes
-
Approaches & Techniques
- Approaches & Techniques
- CDH (Target Gene Fragmentation)
- Cryogenic Electron Microscopy (Cryo-EM)
- Differential Scanning Fluorimetry (DSF) and nanoDSF Services
- Direct-to-Biology (D2B)
- Dynamic Light Scattering (DLS)
- eProtein Discovery
- Flow Cytometry
- Fragment Based Drug Discovery (FBDD)
- FragmentBuilder
- Grating-Coupled Interferometry
- High Throughput Screening
- Isothermal Titration Calorimetry (ITC)
- LeadBuilder
- PoLiPa (Membrane Protein Solubilisation)
- Spectral Shift and MST Services
- Structure Based Drug Design (SBDD)
- Surface Plasmon Resonance (SPR)
- X-ray Crystallography
-
Offerings
- Library
- News & Events
- Careers